One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...

Imaavy (Nipocalimab-aahu ), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults and adolescents with anti-acetylcholine ...

The neonatal Fc receptor (FcRn) plays a crucial role in maintaining IgG homeostasis by binding to immunoglobulins in a pH-dependent manner. This receptor not only recycles IgG, thereby extending ...

Immunovant, Inc. (NASDAQ:IMVT) is one of the best oversold NASDAQ stocks to buy now. On July 10, Goldman Sachs analyst ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

The National Organization for Rare Disorders (NORD®) is honoring a distinguished group of industry leaders and individuals for their contributions to help improve the lives of more than 30 million ...

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages. | In a quarterly update, the FDA said it’s evaluating the need ...